Drug–Target Kinetics in Drug Discovery

par Tonge, Peter J.
Publié dans ACS Chem Neurosci (2017)

Quantifying the Interactions between Biomolecules: Guidelines for Assay Design and Data Analysis

par Tonge, Peter J.
Publié dans ACS Infect Dis (2019)

Mechanism and Inhibition of the FabV Enoyl-ACP Reductase from Burkholderia Mallei

par Lu, Hao, Tonge, Peter J.
Publié 2010

Drug-Target Residence Time: Critical Information for Lead Optimization

par Lu, Hao, Tonge, Peter J
Publié 2010

Targeting InhA, the FASII Enoyl-ACP Reductase: SAR Studies on Novel Inhibitor Scaffolds

par Pan, Pan, Tonge, Peter J.
Publié dans Curr Top Med Chem (2012)

EDITORIAL OVERVIEW

par Whitty, Adrian, Tonge, Peter J.
Publié dans Curr Opin Chem Biol (2018)

Pharmacokinetic-Pharmacodynamic Models that Incorporate Drug-Target Binding Kinetics

par Daryaee, Fereidoon, Tonge, Peter J.
Publié dans Curr Opin Chem Biol (2019)

The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: Adduct affinity and drug resistance

par Rawat, Richa, Whitty, Adrian, Tonge, Peter J.
Publié 2003

Structure-Kinetic Relationships that Control the Residence Time of Drug-Target Complexes: Insights from Molecular Structure and Dynamics

par Lu, Hao, Iuliano, James N., Tonge, Peter J.
Publié dans Curr Opin Chem Biol (2018)

Mechanism-based inhibitors of MenE, an acyl-CoA synthetase involved in bacterial menaquinone biosynthesis

par Lu, Xuequan, Zhang, Huaning, Tonge, Peter J., Tan, Derek S.
Publié 2008

Stereoselective Synthesis, Docking, and Biological Evaluation of Difluoroindanediol-Based MenE Inhibitors as Antibiotics

par Evans, Christopher E., Matarlo, Joe S., Tonge, Peter J., Tan, Derek S.
Publié dans Org Lett (2016)

Probing mechanisms of resistance to the tuberculosis drug isoniazid: Conformational changes caused by inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis

par Kruh, Nicole A., Rawat, Richa, Ruzsicska, Béla P., Tonge, Peter J.
Publié 2007

Crystal structures of Mycobacterium tuberculosis KasA show mode of action within cell wall biosynthesis and its inhibition by thiolactomycin

par Luckner, Sylvia R., Machutta, Carl A., Tonge, Peter J., Kisker, Caroline
Publié 2009

Elucidation of the protonation states of the catalytic residues in mtKasA - Implications for inhibitor design

par Lee, Wook, Luckner, Sylvia R., Kisker, Caroline, Tonge, Peter. J., Engels, B.
Publié dans Biochemistry (2011)

Correlating Drug-Target Residence Time and Post-Antibiotic Effect: Insight into Target Vulnerability

par Davoodi, Shabnam, Daryaee, Fereidoon, Chang, Andrew, Walker, Stephen G., Tonge, Peter J.
Publié dans ACS Infect Dis (2020)

Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei

par Liu, Nina, Cummings, Jason E., England, Kathleen, Slayden, Richard A., Tonge, Peter J.
Publié 2011

Substrate Recognition by β-Ketoacyl-ACP Synthases()

par Borgaro, Janine G., Chang, Andrew, Machutta, Carl A., Zhang, Xujie, Tonge, Peter J.
Publié 2011

A Novel Interaction Linking the FAS-II and Phthiocerol Dimycocerosate (PDIM) Biosynthetic Pathways

par Kruh, Nicole A., Borgaro, Janine G., Ruzsicska, Béla P., Xu, Hua, Tonge, Peter J.
Publié 2008

A Slow, Tight Binding Inhibitor of InhA, the Enoyl-Acyl Carrier Protein Reductase from Mycobacterium tuberculosis

par Luckner, Sylvia R., Liu, Nina, am Ende, Christopher W., Tonge, Peter J., Kisker, Caroline
Publié 2010

Radiosynthesis and Bioimaging of the Tuberculosis Chemotherapeutics Isoniazid, Rifampicin and Pyrazinamide in Baboons

par Liu, Li, Xu, Youwen, Shea, Colleen, Fowler, Joanna S., Hooker, Jacob M., Tonge, Peter J.
Publié 2010